• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Smiley Andrea Heslin

    6/27/25 5:31:33 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Smiley Andrea Heslin

    (Last) (First) (Middle)
    C/O ATAI LIFE SCIENCES N.V.
    PROF. J.H. BAVINCKLAAN 7

    (Street)
    AMSTERDAM P7 1183 AT

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ATAI Life Sciences N.V. [ ATAI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/26/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $2.25 06/26/2025 A 103,000 (1) 06/26/2035 Common Shares 103,000 $0 103,000 D
    Explanation of Responses:
    1. The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026.
    /s/ Ryan Barrett, Attorney-in-fact 06/27/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ATAI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ATAI

    DatePrice TargetRatingAnalyst
    4/4/2025Buy
    Berenberg
    11/18/2024$15.00 → $10.00Buy
    H.C. Wainwright
    4/3/2024$6.00Hold → Buy
    Maxim Group
    11/1/2022$18.00Buy
    Loop Capital
    11/30/2021$25.00Buy
    Maxim Group
    11/22/2021$40.00 → $50.00Buy
    HC Wainwright & Co.
    11/16/2021$25.00 → $24.00Outperform
    Credit Suisse
    11/16/2021$19.00 → $17.00Sector Perform
    RBC Capital
    More analyst ratings

    $ATAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • atai Life Sciences Announces $50 Million Private Placement Financing

      NEW YORK and AMSTERDAM, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced it had entered into subscription agreements relating to the purchase of 18,264,840 ordinary shares of atai with a nominal value of €0.10 per share ("Common Shares") and pre-funded warrant to purchase 4,566,210 Common Shares (the "Pre-Funded Warrant"). The financing is expected to result in gross proceeds of approximately $50 million, before deducting placement agents' fees and other expenses. The net proceeds from the financing are expec

      7/1/25 6:05:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

      Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t

      7/1/25 6:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

      Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S

      6/2/25 6:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    SEC Filings

    See more
    • SEC Form DEFA14A filed by ATAI Life Sciences N.V.

      DEFA14A - ATAI Life Sciences N.V. (0001840904) (Filer)

      7/1/25 9:30:39 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ATAI Life Sciences N.V.

      DEFA14A - ATAI Life Sciences N.V. (0001840904) (Filer)

      7/1/25 9:30:12 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ATAI Life Sciences N.V. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - ATAI Life Sciences N.V. (0001840904) (Filer)

      7/1/25 7:16:59 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Berenberg initiated coverage on atai Life Sciences N.V.

      Berenberg initiated coverage of atai Life Sciences N.V. with a rating of Buy

      4/4/25 8:27:07 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on atai Life Sciences N.V. with a new price target

      H.C. Wainwright reiterated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $10.00 from $15.00 previously

      11/18/24 11:31:29 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences N.V. upgraded by Maxim Group with a new price target

      Maxim Group upgraded atai Life Sciences N.V. from Hold to Buy and set a new price target of $6.00

      4/3/24 8:14:20 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Apeiron Investment Group Ltd. bought $2,520,000 worth of shares (1,800,000 units at $1.40) (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      3/24/25 5:00:18 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Apeiron Investment Group Ltd. bought $22,755,008 worth of shares (10,835,718 units at $2.10) (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      2/19/25 6:00:05 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brand Florian bought $23,120 worth of shares (20,000 units at $1.16), increasing direct ownership by 18% to 130,000 units (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      11/20/23 9:17:41 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Leadership Updates

    Live Leadership Updates

    See more
    • atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

      - Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.

      1/10/25 7:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

      NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati

      5/23/24 7:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

      NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off

      2/6/24 5:00:31 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Financials

    Live finance-specific insights

    See more
    • atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

      Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t

      7/1/25 6:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

      Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S

      6/2/25 6:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

      Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intravenous psilocin) complement atai's existing drug development programs Multiple clinical readouts anticipated from this investment in Beckley Psytech within next 12 months, including a Phase 2b readout of BPL-003 in Treatment Resistant Depression in 2H24 BPL-003 has the potential to become a first-in-class short-duration psychedelic treatment with rapid acting and durable antidepressant effects Anticipated synergies th

      1/4/24 7:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by ATAI Life Sciences N.V.

      SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

      9/27/24 7:56:26 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

      SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

      5/3/24 4:06:02 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

      SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

      3/12/24 9:30:31 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hoffman John Francis

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      6/27/25 5:31:24 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Johnson Sabrina Martucci

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      6/27/25 5:31:27 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kalali Amir H

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      6/27/25 5:31:28 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care